Hexagon Capital Partners LLC Sells 212 Shares of CVS Health Co. (NYSE:CVS)

Hexagon Capital Partners LLC cut its position in shares of CVS Health Co. (NYSE:CVSGet Rating) by 3.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,220 shares of the pharmacy operator’s stock after selling 212 shares during the period. Hexagon Capital Partners LLC’s holdings in CVS Health were worth $528,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Acropolis Investment Management LLC grew its stake in shares of CVS Health by 77.1% during the first quarter. Acropolis Investment Management LLC now owns 3,018 shares of the pharmacy operator’s stock valued at $305,000 after buying an additional 1,314 shares during the last quarter. Glassy Mountain Advisors Inc. grew its position in CVS Health by 1.1% in the 1st quarter. Glassy Mountain Advisors Inc. now owns 72,680 shares of the pharmacy operator’s stock valued at $7,356,000 after acquiring an additional 825 shares during the last quarter. Zeke Capital Advisors LLC increased its stake in CVS Health by 31.7% in the third quarter. Zeke Capital Advisors LLC now owns 12,182 shares of the pharmacy operator’s stock worth $1,034,000 after purchasing an additional 2,933 shares during the period. Auxier Asset Management lifted its position in shares of CVS Health by 1.0% during the third quarter. Auxier Asset Management now owns 108,859 shares of the pharmacy operator’s stock worth $9,238,000 after purchasing an additional 1,093 shares during the last quarter. Finally, Farmers & Merchants Investments Inc. boosted its stake in shares of CVS Health by 1.5% during the fourth quarter. Farmers & Merchants Investments Inc. now owns 263,517 shares of the pharmacy operator’s stock valued at $27,184,000 after purchasing an additional 3,894 shares during the period. Institutional investors own 78.00% of the company’s stock.

Several research firms have issued reports on CVS. Sanford C. Bernstein cut shares of CVS Health from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $122.00 to $112.00 in a research report on Thursday, May 26th. StockNews.com started coverage on CVS Health in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on CVS Health from $110.00 to $113.00 in a research report on Thursday, May 5th. Tigress Financial increased their price target on CVS Health from $122.00 to $125.00 in a research report on Thursday, April 7th. Finally, Loop Capital started coverage on CVS Health in a research note on Thursday, June 16th. They set a “buy” rating and a $120.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $116.05.

CVS Health stock opened at $91.29 on Thursday. CVS Health Co. has a 1-year low of $79.33 and a 1-year high of $111.25. The business has a fifty day moving average price of $97.08 and a 200-day moving average price of $101.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.88 and a quick ratio of 0.62. The stock has a market capitalization of $119.71 billion, a price-to-earnings ratio of 15.16, a PEG ratio of 1.44 and a beta of 0.78.

CVS Health (NYSE:CVSGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The company had revenue of $76.83 billion during the quarter, compared to analysts’ expectations of $75.30 billion. During the same period last year, the business posted $2.04 earnings per share. The firm’s revenue was up 11.2% compared to the same quarter last year. On average, equities research analysts anticipate that CVS Health Co. will post 8.34 earnings per share for the current fiscal year.

In other news, EVP Prem S. Shah sold 5,346 shares of the firm’s stock in a transaction dated Wednesday, March 30th. The stock was sold at an average price of $104.70, for a total value of $559,726.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Prem S. Shah sold 16,954 shares of the company’s stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $105.00, for a total value of $1,780,170.00. Following the completion of the sale, the executive vice president now owns 43,453 shares in the company, valued at approximately $4,562,565. The disclosure for this sale can be found here. Insiders sold a total of 77,659 shares of company stock valued at $7,882,993 over the last quarter. 0.69% of the stock is owned by company insiders.

CVS Health Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Further Reading

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.